MIRM vs. ROIV, ASND, BPMC, RVMD, BBIO, LNTH, LEGN, ELAN, CYTK, and NUVL
Should you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Lantheus (LNTH), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.
Mirum Pharmaceuticals vs.
Mirum Pharmaceuticals (NASDAQ:MIRM) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.
Roivant Sciences has a net margin of 3,827.42% compared to Mirum Pharmaceuticals' net margin of -31.69%. Roivant Sciences' return on equity of -14.65% beat Mirum Pharmaceuticals' return on equity.
Mirum Pharmaceuticals received 79 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 77.27% of users gave Roivant Sciences an outperform vote while only 75.58% of users gave Mirum Pharmaceuticals an outperform vote.
64.8% of Roivant Sciences shares are held by institutional investors. 22.9% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 7.9% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Mirum Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.
Mirum Pharmaceuticals presently has a consensus price target of $57.10, indicating a potential upside of 22.22%. Roivant Sciences has a consensus price target of $17.93, indicating a potential upside of 60.65%. Given Roivant Sciences' higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Mirum Pharmaceuticals.
Roivant Sciences has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Mirum Pharmaceuticals and Mirum Pharmaceuticals both had 6 articles in the media. Roivant Sciences' average media sentiment score of 0.95 beat Mirum Pharmaceuticals' score of 0.89 indicating that Roivant Sciences is being referred to more favorably in the news media.
Summary
Roivant Sciences beats Mirum Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Mirum Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mirum Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:MIRM) was last updated on 1/22/2025 by MarketBeat.com Staff
